Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Announces Grant of Restricted Share Units

GlobeNewswire March 31, 2023

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2022

GlobeNewswire March 21, 2023

BioSyent Schedules Q4 and Full Year 2022 Earnings Release for March 21, 2023

GlobeNewswire March 9, 2023

BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45

GlobeNewswire March 7, 2023

BioSyent Declares First Quarter 2023 Dividend

GlobeNewswire February 1, 2023

BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product

GlobeNewswire December 14, 2022

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire December 13, 2022

BioSyent Releases Q3 and YTD 2022 Financial Results

GlobeNewswire November 16, 2022

BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022

GlobeNewswire November 10, 2022

BioSyent Initiates First Dividend

GlobeNewswire October 12, 2022

BioSyent to Present at the Virtual MicroCap Leadership Summit

GlobeNewswire September 14, 2022

BioSyent Announces Adoption of Dividend Policy

GlobeNewswire August 23, 2022

BioSyent Releases Q2 and H1 2022 Financial Results

GlobeNewswire August 23, 2022

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

GlobeNewswire August 16, 2022

BioSyent Releases Financial Results for Q1 2022

GlobeNewswire May 18, 2022

BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022

GlobeNewswire May 10, 2022

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year

GlobeNewswire May 2, 2022

BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 26, 2022

BioSyent Announces Grant of Restricted Share Units

GlobeNewswire March 31, 2022

FAX Capital Corp. Reports Fourth Quarter and 2021 Results

GlobeNewswire March 29, 2022